Akebia Therapeutics (AKBA) PT Raised to $25 at Aegis Capital; Deal Lifts Financial Overhang

April 26, 2017 8:01 AM EDT Send to a Friend
Aegis Capital raised its price target on Akebia Therapeutics (NASDAQ: AKBA) to $25.00 (from $21.00) while ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login